A diversified clinical-stage pipeline shaped by:
- Clear understanding of cancer pathways (systems biology)
- Treatments designed with pharmacological properties to match disease need
- Biomarker-driven clinical strategies with clear clinical rationale
Merrimack has a proven history of successfully discovering and developing novel therapeutics that have helped to shape new treatment strategies for patients. That includes the successful development and approval for ONIVYDE®1 (irinotecan liposome injection) to treat patients with advanced pancreatic cancer who have previously been treated with gemcitabine-based chemotherapy.
Today, that journey continues. Merrimack is developing a new generation of solutions for cancer through a focused pipeline of precise, targeted therapies. A cornerstone of our development strategy is to establish efficacy and value through clinical studies in biomarker-enriched patient populations.
1ONIVYDE® was acquired by Ipsen S.A. in April 2017.
Learn more about our ongoing studies at clinicaltrials.gov.
In addition to our existing focused clinical pipeline, we are taking a systematic approach to our preclinical development work.
These and other innovative programs utilizing our biomarker-driven approach will provide future opportunities to enter the clinic to help patients in need.
Adiwijaya et al., ASCO, 2018.
Schoeberl et al., Nature Partner Journals: Systems Biology and Application, 2017.
Camblin et al., Clinical Cancer Research, 2018.
Isakoff et al., AACR-NCI-EORTC, 2016.
Kamoun et al., AACR, 2018.
Kamoun et al., AACR, 2017.
Alkan et al., AACR, 2018.
Hass et al., AACR, 2018.
Tam et al., AACR, 2018.
Discovering and developing breakthrough cancer solutions takes a collaborative effort.
Learn more about how to work with us here.